GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » Debt-to-EBITDA

Bio View (XTAE:BIOV) Debt-to-EBITDA : N/A (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Bio View Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bio View's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪1.56 Mil. Bio View's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪1.95 Mil. Bio View's annualized EBITDA for the quarter that ended in Dec. 2023 was ₪0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bio View's Debt-to-EBITDA or its related term are showing as below:

XTAE:BIOV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.5   Med: 1.05   Max: 1.56
Current: 1.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bio View was 1.56. The lowest was 0.50. And the median was 1.05.

XTAE:BIOV's Debt-to-EBITDA is ranked worse than
50.34% of 437 companies
in the Medical Devices & Instruments industry
Industry Median: 1.25 vs XTAE:BIOV: 1.26

Bio View Debt-to-EBITDA Historical Data

The historical data trend for Bio View's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View Debt-to-EBITDA Chart

Bio View Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.61 1.05 1.56 1.20

Bio View Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -208.45 0.93 0.63 N/A N/A

Competitive Comparison of Bio View's Debt-to-EBITDA

For the Medical Devices subindustry, Bio View's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio View's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bio View's Debt-to-EBITDA falls into.



Bio View Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bio View's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.555 + 1.951) / 2.926
=1.20

Bio View's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.555 + 1.951) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Bio View  (XTAE:BIOV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bio View Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bio View's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio View (XTAE:BIOV) Business Description

Traded in Other Exchanges
N/A
Address
3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View (XTAE:BIOV) Headlines

No Headlines